Furthermore, a single application of a GFHPD to CRC-bearing mice displayed comparable therapeutic efficacy to an EGFR-directed antibody-based therapy, while the combination of both strategies did not result in an additive effect. Here, EGFR is linked to colorectal carcinoma.